Stock ENZN ENZON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Enzon Pharmaceuticals, Inc.

Equities

ENZN

US2939041081

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 12:14:27 11/05/2024 am IST 		5-day change 1st Jan Change
0.0868 USD -3.61% Intraday chart for Enzon Pharmaceuticals, Inc. +15.73% -7.26%
20/03 Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 11.14 9.108 18.43 25.42 18.31 6.943
Enterprise Value (EV) 1 4.642 3.662 -29.71 -22.22 -28.68 -40.07
P/E ratio 1.9 x -9.3 x -7.17 x -10.2 x -12.5 x 70.9 x
Yield - - - - - -
Capitalization / Revenue 1.61 x 44 x 355 x 36.3 x 704 x -
EV / Revenue 0.67 x 17.7 x -571 x -31.7 x -1,103 x -
EV / EBITDA - - - - - -
EV / FCF -1.12 x 0.54 x 80.4 x 68.4 x -79.9 x 71.1 x
FCF Yield -89.1% 185% 1.24% 1.46% -1.25% 1.41%
Price to Book 0.74 x 1.5 x 2.5 x 5.22 x 5.37 x 1.98 x
Nbr of stocks (in thousands) 44,215 44,215 74,215 74,215 74,215 74,215
Reference price 2 0.2520 0.2060 0.2484 0.3425 0.2466 0.0936
Announcement Date 21/02/19 19/02/20 23/02/21 25/02/22 16/02/23 20/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 6.918 0.207 0.052 0.701 0.026 -
EBITDA - - - - - -
EBIT 1 5.855 -0.973 -1.305 -0.469 -1.032 -1.044
Operating Margin 84.63% -470.05% -2,509.62% -66.9% -3,969.23% -
Earnings before Tax (EBT) 1 5.855 -0.973 -1.304 -0.462 -0.386 1.217
Net income 1 5.849 -0.979 -1.311 -0.469 -0.186 1.373
Net margin 84.55% -472.95% -2,521.15% -66.9% -715.38% -
EPS 2 0.1323 -0.0221 -0.0347 -0.0336 -0.0197 0.001320
Free Cash Flow 1 -4.138 6.791 -0.3696 -0.3251 0.359 -0.5635
FCF margin -59.81% 3,280.62% -710.82% -46.38% 1,380.77% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 21/02/19 19/02/20 23/02/21 25/02/22 16/02/23 20/03/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 6.5 5.45 48.1 47.6 47 47
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -4.14 6.79 -0.37 -0.33 0.36 -0.56
ROE (net income / shareholders' equity) 48.5% -9.3% -4.87% -0.99% -0.4% 2.99%
ROA (Net income/ Total Assets) 29.2% -5.53% -2.98% -0.61% -1.35% -1.37%
Assets 1 20 17.7 43.97 76.8 13.75 -100.3
Book Value Per Share 2 0.3400 0.1400 0.1000 0.0700 0.0500 0.0500
Cash Flow per Share 2 0.1500 0.1200 0.6500 0.6400 0.6300 0.6300
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 21/02/19 19/02/20 23/02/21 25/02/22 16/02/23 20/03/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENZON PHARMACEUTICALS, INC. Stock Enzon Pharmaceuticals, Inc.
-7.26% 6.44M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ENZN Stock
  4. Financials Enzon Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW